Vinay Prasad exits FDA, therapy firms get approvals
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Tim Hunt highlighted recent FDA approvals for rare‑disease treatments from Rocket Pharmaceuticals and Regeneron as a sign of progress.
- Vinay Prasad left the FDA last week, ending his role as chief regulator of gene and cell therapies and vaccines.
- Sanofi asked to withdraw its diabetes drug from the FDA’s priority review voucher program after a political appointee intervened.
Why it matters: Gene therapy firms like Rocket and Regeneron benefit from recent FDA approvals, but the departure of Vinay Prasad last week fuels regulatory uncertainty that raises the risk of delayed gene therapy launches and erodes investor confidence.
